SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ipca Laboratories gets nod to merge Tonira Pharma with itself

19 Sep 2011 Evaluate

Ipca Laboratories has received an approval for amalgamation of Tonira Pharma with the company with effect from April 01, 2011 being the appointed date through a scheme of amalgamation. The board at its meeting held on September 17, 2011 has considered and approved the same. However, the proposed scheme of amalgamation will be subject to all necessary permissions and approvals, as may be required.

Further, the scheme envisages an exchange ratio of six equity shares of Rs 2 each fully paid-up of Ipca Laboratories for every one hundred equity shares of Rs 10 each fully paid-up of Tonira Pharma. The exchange ratio is based on the joint valuation made by Natvarlal Vepari & Company, Chartered Accountants and G. M. Kapadia & Company, Chartered Accountants.

Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.

Tonira Pharma is engaged in the business of manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) and intermediates. Tonira undertakes contract synthesis both on exclusive and non-exclusive basis.  The company has the capability to provide contract research and manufacturing services to its customers.

Ipca Laboratories Share Price

1537.00 6.40 (0.42%)
05-May-2026 09:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1803.60
Dr. Reddys Lab 1282.40
Cipla 1323.85
Zydus Lifesciences 904.95
Lupin 2346.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×